Pharming Group (PHAR) Price & Analysis

Compare

169 Followers

PHAR Stock Chart & Stats

$14.21

-$0.05(-0.51%)

At close: Jan 08 4:00 PM EST

$14.21

-$0.05(-0.51%)

Day’s Range― - ―

52-Week Range$7.50 - $17.86

Previous CloseN/A

Volume181.00

Average Volume (3M)14.71K

Market Cap

$1.16B

Enterprise Value$957.53M

Total Cash (Recent Filing)$141.54M

Total Debt (Recent Filing)$111.52M

Price to Earnings (P/E)1223.6

Beta0.37

Next Earnings

Mar 12, 2026

EPS Estimate

0.02

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.10

Shares Outstanding68,514,760

10 Day Avg. Volume22,068

30 Day Avg. Volume14,708

Financial Highlights & Ratios

PEG Ratio-3.28

Price to Book (P/B)3.03

Price to Sales (P/S)2.26

P/FCF Ratio-258.67

Enterprise Value/Market Cap0.83

Enterprise Value/Revenue2.64

Enterprise Value/Gross Profit2.94

Enterprise Value/Ebitda21.41

Forecast

1Y Price Target

$39.50

Price Target Upside177.97% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Financial PerformancePharming announced 3Q25 financial results, with revenue exceeding estimates for both Ruconest and Joenja.

Product GrowthJoenja has continued to deliver meaningful growth since its launch approximately 2 years ago, with the commercial story growing and on solid footing.

Regulatory ApprovalApproval of the sNDA for pediatric APDS patients for Joenja would unlock a new patient population, increase sales growth, and support further upside for the stock.

Bears Say

Pharming Group News

Pharming price target raised to $42 from $41 at Oppenheimer

Oppenheimer raised the firm’s price target on Pharming (PHAR) to $42 from $41 and keeps an Outperform rating...

1M ago

PHAR

Pharming Group Reports Strong Q3 2025 Growth

Pharming Group Nv ( ($PHAR) ) has released its Q3 earnings. Here is a breakdown of the information...

1M ago

PHAR

Pharming Group Reports Strong Q3 2025 Financial Growth and Strategic Updates

Pharming Group ( ($PHAR) ) just unveiled an announcement. Pharming Group reported significant financial growth in the third...

1M ago

PHAR

Pharming Group to Present New Data at ACAAI 2025

Pharming Group ( ($PHAR) ) just unveiled an update. On October 20, 2025, Pharming Group announced that 12...

2M ago

PHAR

Pharming Group Announces Restructuring to Cut Costs and Boost Growth

An announcement from Pharming Group ( ($PHAR) ) is now available. On October 6, 2025, Pharming Group announced...

2M ago

PHAR

Pharming announces 20% net reduction in non-commercial, non-medical headcount

Pharming (PHAR) Group announced the implementation of an organizational restructuring to accelerate the Company’s growth. The restructuring is...

2M ago

PHAR

Pharming Group’s Leniolisib Gains FDA Approval for Pediatric Use, Expanding Market Potential

Analyst Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Pharming Group and keeping the price target...

2M ago

PHAR

Pharming Group’s Leniolisib Receives FDA Priority Review for Pediatric APDS Treatment

Pharming Group ( ($PHAR) ) has shared an update. On October 1, 2025, Pharming Group announced that the...

2M ago

PHAR

Pharming Group Joins Euronext AMX® Index Reflecting Growth Momentum

Pharming Group ( ($PHAR) ) has provided an update. On September 10, 2025, Pharming Group N.V. announced its...

3M ago

PHAR

Pharming Group Appoints Kenneth Lynard as CFO Amid Strong Financial Performance

Pharming Group ( ($PHAR) ) just unveiled an update. On September 2, 2025, Pharming Group announced the appointment...

3M ago

PHAR

= Pharming Group NV ADS trading resumes

12:06 EDT = Pharming (PHAR) Group NV ADS trading resumes Published first on TheFly – the ultimate source...

4M ago

PHAR

= Pharming Group NV ADS trading halted, volatility trading pause

11:41 EDT = Pharming (PHAR) Group NV ADS trading halted, volatility trading pause Published first on TheFly –...

4M ago

PHAR

Pharming price target raised to EUR 2.45 from EUR 2 at RBC Capital

RBC Capital raised the firm’s price target on Pharming (PHAR) to EUR 2.45 from EUR 2 and keeps...

4M ago

PHAR

Pharming price target raised to $41 from $40 at Oppenheimer

Oppenheimer analyst Jeff Jones raised the firm’s price target on Pharming (PHAR) to $41 from $40 and keeps...

4M ago

PHAR

PHAR FAQ

What was Pharming Group Nv’s price range in the past 12 months?

Pharming Group Nv lowest stock price was $7.50 and its highest was $17.86 in the past 12 months.

What is Pharming Group Nv’s market cap?

Pharming Group Nv’s market cap is $1.16B.

When is Pharming Group Nv’s upcoming earnings report date?

Pharming Group Nv’s upcoming earnings report date is Mar 12, 2026 which is in 91 days.

How were Pharming Group Nv’s earnings last quarter?

Pharming Group Nv released its earnings results on Nov 06, 2025. The company reported $0.1 earnings per share for the quarter, beating the consensus estimate of $0.004 by $0.096.

Is Pharming Group Nv overvalued?

According to Wall Street analysts Pharming Group Nv’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Pharming Group Nv pay dividends?

Pharming Group Nv does not currently pay dividends.

What is Pharming Group Nv’s EPS estimate?

Pharming Group Nv’s EPS estimate is 0.02.

How many shares outstanding does Pharming Group Nv have?

Pharming Group Nv has 68,514,760 shares outstanding.

What happened to Pharming Group Nv’s price movement after its last earnings report?

Pharming Group Nv reported an EPS of $0.1 in its last earnings report, beating expectations of $0.004. Following the earnings report the stock price went up 11.533%.

Which hedge fund is a major shareholder of Pharming Group Nv?

Currently, no hedge funds are holding shares in PHAR

Pharming Group Stock Smart Score

Outperform

Fundamentals

Return on Equity

0.44%

Trailing 12-Months

Asset Growth

11.34%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Pharming Group Nv

Pharming Group N.V. is a biopharmaceutical company based in the Netherlands that focuses on the development and commercialization of innovative therapies for rare diseases. The company specializes in the production of recombinant proteins through its proprietary technology platform, which enables the manufacturing of complex biopharmaceuticals. Pharming's core product is Ruconest, a recombinant C1 esterase inhibitor used for the treatment of acute attacks of hereditary angioedema. The company is also involved in developing new therapies that leverage its technology for additional indications.

Pharming Group (PHAR) Earnings & Revenues

Historic Earnings Reports

PHAR Company Deck

PHAR Earnings Call

Q3 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call reflects a strong financial performance with significant revenue growth and an optimistic future outlook. The primary growth drivers, RUCONEST and Joenja, have performed exceptionally well, and the upgraded revenue guidance underscores company confidence. However, challenges exist with the international market withdrawal of RUCONEST and the VUS reclassification timeline. Overall, the positive aspects outweigh the challenges.View all PHAR earnings summaries

PHAR Stock 12 Month Forecast

Average Price Target

$39.50

▲(177.97% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"6":"$6","43":"$43","15.25":"$15.25","24.5":"$24.5","33.75":"$33.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":42,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$42.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":39.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$39.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":37,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$37.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[6,15.25,24.5,33.75,43],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,16.23,18.212307692307693,20.194615384615386,22.176923076923078,24.15923076923077,26.14153846153846,28.123846153846152,30.106153846153845,32.08846153846154,34.07076923076923,36.05307692307692,38.035384615384615,40.01769230769231,{"y":42,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,16.23,18.02,19.810000000000002,21.6,23.39,25.18,26.97,28.76,30.55,32.34,34.129999999999995,35.92,37.71,{"y":39.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,16.23,17.82769230769231,19.425384615384615,21.023076923076925,22.62076923076923,24.21846153846154,25.816153846153846,27.413846153846155,29.011538461538464,30.60923076923077,32.206923076923076,33.80461538461539,35.402307692307694,{"y":37,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":8.59,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.52,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.55,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.06,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.68,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.62,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.75,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.24,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.71,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.96,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.39,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.1,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.23,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >